Long-term Efficacy Results of EORTC Genito-urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients with Intermediate- And...

Overview

Journal Eur Urol

Specialty Urology

Date 2009 Dec 26

PMID 20034729

Citations 117

Authors

Richard J Sylvester

Maurizio A Brausi

Wim J Kirkels

Wolfgang Hoeltl

Fernando Calais da Silva

Philip H Powell

Stephen Prescott

Ziya Kirkali

Cees van de Beek

Thierry Gorlia

Theo M de Reijke

Affiliations

Soon will be listed here.

Abstract

Background: Intravesical chemotherapy and bacillus Calmette-Guérin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients.

Objective: The aim of the study was to compare the long-term efficacy of BCG and epirubicin.

Design, Setting, And Participants: From January 1992 to February 1997, 957 patients with intermediate- or high-risk stage Ta T1 urothelial bladder cancer were randomized after transurethral resection to one of three treatment groups in the European Organization for Research and Treatment of Cancer Genito-Urinary Group phase 3 trial 30911.

Intervention: Patients received six weekly instillations of epirubicin, BCG, or BCG plus isoniazid (INH) followed by three weekly maintenance instillations at months 3, 6, 12, 18, 24, 30, and 36.

Measurements: End points were time to recurrence, progression, distant metastases, overall survival, and disease-specific survival.

Results And Limitations: With 837 eligible patients and a median follow-up of 9.2 yr, time to first recurrence (p<0.001), distant metastases (p=0.046), overall survival (p=0.023), and disease-specific survival (p=0.026) were significantly longer in the two BCG arms combined as compared with epirubicin; however, there was no difference for progression. Three hundred twenty-three patients with stage T1 or grade 3 tumors were high risk, and the remaining 497 patients were intermediate risk. The observed treatment benefit was at least as large, if not larger, in the intermediate-risk patients compared with the high-risk patients.

Conclusions: In patients with intermediate- and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival. The benefit of BCG is not limited to just high-risk patients; intermediate-risk patients also benefit from BCG.

Trial Registration: This study was registered with the US National Cancer Institute clinical trials database [protocol ID: EORTC-30911]. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=77075&version=HealthProfessional&protocolsearchid=6540260.

Citing Articles

Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study.

Aksakalli T, Utlu A, Celik F, Cinislioglu A, Demirdogen S, Atar M BMC Urol. 2025; 25(1):49.

PMID: 40075319 PMC: 11900595. DOI: 10.1186/s12894-025-01734-6.

Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.

Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P Curr Oncol Rep. 2025; .

PMID: 39976835 DOI: 10.1007/s11912-025-01645-7.

Long-term efficacy of two sequential induction courses of Bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.

Seo H, Jung E, Song G Transl Androl Urol. 2025; 14(1):4-7.

PMID: 39974797 PMC: 11833530. DOI: 10.21037/tau-24-466.

Review of BCG immunotherapy for bladder cancer.

Liatsos G, Mariolis I, Hadziyannis E, Bamias A, Vassilopoulos D Clin Microbiol Rev. 2025; 38(1):e0019423.

PMID: 39932308 PMC: 11905372. DOI: 10.1128/cmr.00194-23.

Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis.

Chen Z, Chen X, Li D, Jian J, Yao C, Wei X BMC Urol. 2025; 25(1):19.

PMID: 39875945 PMC: 11776312. DOI: 10.1186/s12894-024-01675-6.

References

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

Bohle A, Jocham D, Bock P . Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2002; 169(1):90-5. DOI: 10.1016/S0022-5347(05)64043-8. View

Au J, Badalament R, Wientjes M, Young D, Warner J, Venema P . Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001; 93(8):597-604. DOI: 10.1093/jnci/93.8.597. View

Duchek M, Johansson R, Jahnson S, Mestad O, Hellstrom P, Hellsten S . Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol. 2009; 57(1):25-31. DOI: 10.1016/j.eururo.2009.09.038. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Sylvester R . Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur Urol. 2009; 56(2):266-8. DOI: 10.1016/j.eururo.2009.04.043. View

Bohle A, Bock P . Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004; 63(4):682-6. DOI: 10.1016/j.urology.2003.11.049. View

Bono A, Hall R, Denis L, Lovisolo J, Sylvester R . Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol. 1996; 29(4):385-90. DOI: 10.1159/000473784. View

van der Meijden A, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R . Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer.... J Urol. 2001; 166(2):476-81. DOI: 10.1097/00005392-200108000-00016. View

10.

Sylvester R, Oosterlinck W, Witjes J . The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008; 53(4):709-19. PMC: 2587437. DOI: 10.1016/j.eururo.2008.01.015. View

11.

Vegt P, van der Meijden A, Sylvester R, Brausi M, Holtl W, de Balincourt C . Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol. 1997; 157(4):1246-9. View

12.

Sylvester R, van der Meijden A, Witjes J, Kurth K . Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005; 174(1):86-91. DOI: 10.1097/01.ju.0000162059.64886.1c. View

13.

Shelley M, Kynaston H, COURT J, Wilt T, Coles B, Burgon K . A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001; 88(3):209-16. DOI: 10.1046/j.1464-410x.2001.02306.x. View

14.

Sylvester R, van der Meijden A, Lamm D . Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168(5):1964-70. DOI: 10.1016/S0022-5347(05)64273-5. View

15.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008; 54(2):303-14. DOI: 10.1016/j.eururo.2008.04.051. View

16.

Sylvester R, Oosterlinck W, van der Meijden A . A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171(6 Pt 1):2186-90, quiz 2435. DOI: 10.1097/01.ju.0000125486.92260.b2. View